ZimVie Inc.
zimvie.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Jul 30, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Jul 30, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Designs, manufactures and sells dental implant systems, biomaterials and digital dentistry solutions for oral surgeons, dental clinicians and dental laboratories.
10-K for FY2024, filed Feb 26, 2025Our core services include designing, manufacturing and distributing dental implant systems, dental biomaterial products and digital…View ↗
Dental implant systems. Dental reconstructive implants are for individuals who are missing one or more teeth, or are totally without teeth…View ↗
Biomaterial solutions. Our implant portfolio is complemented by our robust line of biomaterial solutions that are used for soft tissue and…View ↗
Digital dentistry solutions. Digital dentistry is a growing category of the dental market, and we offer a full suite of digital dentistry…View ↗
How Did They Make Money?
Dental customers buy products that are usually sold when shipped or delivered, with payment terms typically less than 90 days; consigned products are invoiced when implanted.
10-K for FY2024, filed Feb 26, 2025
$449.7M
-
10-K for FY2024, filed Feb 26, 2025
$449.7M ↗
Who Were Their Customers?
Oral surgeons, dental specialists, general dentists, dental laboratories and dental organizations buy its products, mostly through direct sales; third-party distributors serve smaller geographies. Sales also go through stocking distributors, healthcare dealers and direct institutional accounts.
10-K for FY2024, filed Feb 26, 2025
Did Revenues Turn Into Profits?
No. It lost $25.8M in FY2024.
10-K for FY2024, filed Feb 26, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Jul 30, 2025
−$3.9MView ↗
- ▼ −2% (Loss)
- vs −$4M in Q2 FY2024
-
Oct 20, 2025
ARCHIMED completed its acquisition of ZimVie, which became privately held
Stockholders received $19.00 in cash per share, and the stock stopped trading on Nasdaq.
Sources
8-K, filed Oct 20, 2025
As described above, at the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, (i) Parent…View ↗
-
Jul 30, 2025
ZimVie withdrew its 2025 financial guidance
The company said its previous financial guidance should not be relied upon.
Sources
8-K, filed Jul 30, 2025
The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by…View ↗
-
Jul 21, 2025
ZimVie agreed to be acquired by ARCHIMED
The agreement would make ZimVie privately held.
Sources
8-K, filed Jul 21, 2025
On July 20, 2025, ZimVie Inc. (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zamboni Parent…View ↗
-
Mar 13, 2025
Board Chair David King planned to leave the board
CEO Vafa Jamali was appointed Board chair, and Vinit Asar was appointed lead independent director.
Sources
8-K, filed Mar 13, 2025
On March 7, 2025, David King, Non-Executive Chair of the Board of Directors (the “Board”) of ZimVie Inc. (the “Company”) and a member of…View ↗
Shrank. Revenue fell 51% in 4 years, from $912.4M in FY2020 to $449.7M in FY2024, about 16% a year.
Spine business sold
The older report described both spine surgery products and dental products; the latest describes only the continuing dental business after the spine segment sale.
10-K for FY2021, filed Mar 31, 2022 10-K for FY2024, filed Feb 26, 2025
Who Did They Compete With?
Competes with The Straumann Group, Dentsply Sirona, Envista Holdings, Henry Schein, and Geistlich Pharma
10-K for FY2024, filed Feb 26, 2025The markets in which we conduct our business, and the medical technology industry in general, are highly competitive and subject to change.…View ↗
Loading...
